key: cord-0784600-52p3771h
authors: Amer, M. R.; Bawazeer, M.; Butt, A. S.; Dahhan, T. I.; Kseibi, E.; Jamil, M. G.
title: Modafinil for Wakefulness in the Critical Care Units: A Case Series including COVID-19 Patients at a Tertiary Care Saudi Hospital
date: 2021-02-19
journal: nan
DOI: 10.1101/2021.02.11.21250832
sha: 17bb2328eddf3c10baf200d35bd85cad6ddddd26
doc_id: 784600
cord_uid: 52p3771h

Cognitive improvement after critical illness is complex. Neuro-stimulants are used to speed up physical and mental processes through the increase in arousal, and wakefulness. In this case series, we reviewed the literature and described the effect of modafinil for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020. A total of 8 patients included; 3 admitted to COVID-19, 4 surgical, and 1 transplant ICU. Obstructive sleep apnea was noted in 2 (25%), 2 patients (25 %) had an initial neuroimaging that showed hemorrhagic stroke, and 1 (12.5%) showed ischemic stroke with hemorrhagic transformation. Modafinil 100-200 mg daily was started for a median duration of 4 days and the median initiation time in relation to ICU admission was 11 (IQR 9-17) days. Glasgow coma Scale improvement was noted on 5 patients (62.5%). The median duration of mechanical ventilation was 17.5 (IQR 15-31.75) days, and the median ICU stay was 28.5 (IQR 20.25-48) days. All-cause mortality rate was 25 % at 28 days and 62.5 % at 90 days. Modafinil prevented tracheostomy in 1 COVID-19 patient. No significant adverse drug reactions were documented. In our case series, we described our experience for modafinil use for wakefulness in ICU ventilated patients including COVID-19 patients. Based on our observations, the known effects of modafinil, and its safety profile, it holds the potential to facilitate recovery from cognitive impairment. Larger studies are warranted to fully evaluate its role for this indication.

Intensive care unit (ICU) patients are susceptible to neurocognitive and musculoskeletal complications 50 because of various factors, such as the nature of critical illness, medications, over-sedation, and pain [1] . 51

Moreover, sleep disruption in ICUs remains an elusive and pervasive problem. The 2018 pain, agitation/ sedation, 52 delirium, immobility, and sleep disruption (PADIS) guidelines included a brief overview of risk factors contributing 53

to disrupted sleep quality (e.g., architecture, fragmentation, sleep quality score), quantity (e.g., latency, and 54 duration), or circadian rhythm in ICUs [2, 3] . Additionally, clinical experience from severe acute respiratory 55 syndrome coronavirus 2 (SARS-CoV-2) suggests its neuro-invasive potential [4] [5] [6] . Approximately 36.4% 56 coronavirus disease 2019 inpatients in a Wuhan hospital exhibited neurological signs and/or 57 symptoms during infection [7] . Manifestations included delirium, confusion, executive dysfunction, anosmia, 58 stroke, headache, Guillain Barré syndrome (GBS), Miller Fisher syndrome, encephalitis, acute necrotizing 59 encephalopathy, myelitis and CNS demyelinating lesions [7, 8] . Moreover, critical illness polyneuropathy and ICU-60 acquired weakness have been observed in 25-46% of ICU patients. Duration of ventilation, corticosteroid 61 administration, multi-organ dysfunction, sepsis, hyperglycemia, and renal replacement therapy have all been 62 correlated with ICU-acquired weakness [9] [10] [11] . However, their incidence is unknown in patients with SARS-CoV-63 2 infection. Case reports of critical-illness polyneuropathy and/or myopathy are rare in patients with SARS-CoV-64 1 and Middle East respiratory syndrome (MERS-CoV), which can be attributed to the low number of correlation 65 studies between these illnesses and the prolonged ICU stay [12, 13] . 66

Early mobilization of these patients has become the standard of care; however, somnolent, fatigued, and 67 depressed patients may not be able or willing to comply and may have a delayed recovery [3] . Neuro-stimulants 68 are used to speed up the physical and mental processes through the increase of dopamine, serotonin, 69 norepinephrine, and acetylcholine. This in turn translates to improved neuro-cognition, enhanced arousal, 70 wakefulness, attention, memory, mental, and motor processing speed [14] . Although, the prescribing trends of 71 neuro-stimulants are yet to be fully elucidated, their use is increasing in traumatic brain injury (TBI) patients 72 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 to sedatives and analgesics after modafinil was started, resulting in an increasing trend of GCS over time. No 98 major adverse effects were observed. The authors concluded that modafinil did prove beneficial in promoting 99 wakefulness in ICU patients. Its impact on overall patient outcomes in the ICU remains unclear and needs further 100 investigation. In order to gain insight on modafinil use for wakefulness in ICU, we reviewed the literature, 101 described 8 patients, and provided additional clinical data about COVID-19 cases admitted to the ICU. Our aim to 102 describe the clinical characteristics for patients who received modafinil to promote wakefulness and improve 103 cognition, and describe the median change in GCS before and after modafinil therapy. The author also sought to 104 describe the safety, ICU course, and outcomes including duration of mechanical ventilation, ICU length of stay 105 (LOS), hospital LOS, and all-cause of mortality rate. older 2) admitted to COVID and non-COVID units between January 2017 and June 2020 3) ICU stay for at least 48 117 h, 4) started on modafinil during ICU stay for at least 48 h, and 5) required ventilatory support. Those who did 118 not receive modafinil or received modafinil for indications other than ICU wakefulness were excluded. The CARE 119 (CAse REport) guidelines checklist was followed in describing each case included in this study [33] . The trial 120 registered retrospectively at clinical trial. gov [ClinicalTrials.gov Identifier: NCT04751227] 121 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Patient demographic data including ICU admission diagnosis, ICU type, comorbidities, and other ICU support 124

[tracheostomy, renal replacement therapy (RRT), steroids, COVID-19 treatment regimen, and vasopressors] were 125 obtained from the electronic medical record (EMR). The status of ventilator use before and after modafinil 126 administration, modafinil initiation time in relation to ICU admission, dose and duration of treatment were also 127 recorded. Severity of illness was evaluated using Sequential Organ Failure Assessment (SOFA) and Acute 128

Physiology and Chronic Health Evaluation (APACHEII) scores. The worst value for baseline laboratory tests was 129 chosen. These data were collected within the first 24 h after admission to the ICU. If that data were not available, 130 then data closest to admission were recorded. Work up for decreased level of consciousness (LOC) was recorded 131 including metabolic abnormalities, neuroimaging [brain computed tomography (CT), and magnetic resonance 132 imaging (MRI)], electroencephalogram (EEG), lumbar puncture, and cerebrospinal fluid (CSF) analysis. The 133 findings of nerve conduction studies (NCS), electromyography (EMG), and other complications during ICU stay 134 were documented. The GCS 48 h before and 168 h (7 days) after modafinil therapy, ICU LOS, hospital LOS, 135 discharge disposition, duration of mechanical ventilation, and mortality rate were recorded. We defined 136 responders for GCS change as a 2 points increase from baseline post modafinil initiation up to 7 days. Duration 137 of mechanical ventilation was recorded as the number of calendar days from intubation to extubation or until 138 ICU discharge, or death whichever occurs first. All-cause mortality rate was reported at 28 and 90 days. The 139 documentation in the EMR was reviewed to identify the patients started on antipsychotics and possible adverse 140 drug reactions (ADRs) related to modafinil including nervousness, agitation, delirium, hypersensitivity, and drug 141 rash. Naranjo scale was used to evaluate the causality of ADRs and modafinil therapy [34] . 142

Continuous variables were presented as mean ± standard deviation (SD) or median (interquartile range [IQR]) as 143 appropriate, and categorical variables were presented as number and frequency (%). The changes in GCS was 144 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 examined graphically over time. Owing to the retrospective and exploratory nature of this case series, no sample 145 size justification is provided. Instead we wish to report all the patients meeting the inclusion criteria which might 146 be useful to other researchers who may want to combine these results with their own in a meta-analytic 147 approach. Descriptive statistical analysis was conducted using IBM SPSS Statistics, windows version 25.0 (IBM 148

Corp., Armonk, NY). 149

Results 150

A total of 8 patients who met the inclusion criteria were described in this case series. The demographics and clinical 152 characteristics are summarized in Table 2 . The median patient age was 76 ) years, 7 (87.5 %) 153 were men, 3 (37.5%) admitted to COVID ICU, and 5 (62.5%) admitted to non-COVID ICU. Regarding the 154 comorbidities, OSA was noted in 2 (25%), and ischemic stroke in 2 (25%). The median SOFA and APACHE II scores 155 were 9.5 (IQR 7.25-11) and 27.5 (IQR 19.5-33), respectively. The median time from ICU admission to modafinil 156 administration was 11 (IQR 9-17) days. Seven patients (87.5%) started on modafinil 100 mg orally every morning 157 while one patient received 200 mg daily for a median duration of 4 days . The main indication for 158 modafinil initiation was decreased LOC and altered mental status that potentially preclude successful extubation 159 or liberation from mechanical ventilation. All patients received vasopressors during the ICU stay, and 5 patients 160 (62.5%) started on RRT for pre-existing chronic kidney disease or acute kidney injury. All COVID-19 patients were 161 treated according to our institution protocol for antivirals and immunomodulatory therapies for possibility of 162 cytokine storm. One patient received 5 days of IVIG as part of COVID-19 regimen (patient #1) and one patient 163 received it for possible GBS (patient #8). 164 165

Follow up and ICU complications 166 Table 3 illustrates the workup for decreased LOC during the ICU stay prior to modafinil initiation. Two patients 167 (25%) had initial neuroimaging that showed hemorrhagic stroke, and one (12.5%) had ischemic stroke with 168 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The median change of GCS 48 h before and 168 h after modafinil therapy is displayed in Fig. 1 . Time 0 the time 181 modafinil was first administered. An improvement was noted in patients # 1, 3, 4, 5, 6. In patient 8, the GCS slightly 182 increased initially after modafinil administration then remains unchanged after that. Patient # 2 and 7, no 183 improvement was noted in GCS after modafinil therapy. 184 CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 In our case series, we described our experience with modafinil for wakefulness in the critical care units including 195 COVID-19 patients at a tertiary care hospital. In majority of the cases, nonpharmacologic measures to 196 encourage a healthy sleep cycle were employed prior to modafinil initiation. Moreover, we addressed multiple 197 potential etiologies for altered mental status prior to modafinil initiation including primary CNS process, 198 metabolic derangements, hypoxemia or hypercarbia due to respiratory failure, renal or hepatic dysfunction, 199 nutritional deficiencies (e.g. thiamine) in patients with poor nutritional status, infection and sepsis induced 200 encephalopathy, medication effects [sedation required for prolonged intubation], EEG to rule out non-201 convulsive seizure, lumbar puncture if the patient's neurological findings were not explained by above studies, 202

and NCS to rule out neuromuscular disorders that could preclude successful extubation. Although we cannot 203 state with certainty that modafinil was the primary reason for improvement of cognition function, the temporal 204 relationship between starting modafinil and patients' improvement makes it a potential contributing factor. 205

The use of modafinil in a population with neurological findings had been examined before and summarized in 206 . This was a single-center, double-blind, placebo-controlled cross-over trial, where 53 participants were 208 randomly assigned to receive up to 400 mg of modafinil, or placebo. After adjusting for baseline scores and 209 period effects, there were no statistically significant differences between improvements seen with modafinil 210 and placebo on Fatigue Severity Scale (FSS) at wk 4 (-0.5 ± 1.88; p = 0.80) or wk 10 (-1.4 ± 2.75; p = 0.61). For 211

Epworth Sleepiness Scale (ESS) for daytime sleepiness, average changes were significantly greater with modafinil 212 than placebo at wk 4 (-1.2 ± 0.49; p = 0.02) but not at wk 10 (-0.5 ± 0.87; p = 0.56). Modafinil was safe and well 213 tolerated, although insomnia was reported significantly more often with modafinil than with placebo (p = 0.03). 214

Another trial in mild to severe TBI patients in ICU used lower dose of modafinil of 100-200 mg or placebo every 215 morning for 6 wk [28] . This prospective, double-blind, randomized, placebo-controlled pilot study was aimed at 216 studying the effect of daily modafinil on post traumatic EDS and fatigue. The EDS improved significantly in 217 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint patients with TBI receiving modafinil treatment, compared to the placebo group. Modafinil, however, had no 218 impact on posttraumatic fatigue. Clinically relevant side effects were not observed. 219 A systematic review for amantadine and modafinil as neuro-stimulants during post-stroke care identified 12,620 220 publications including 12 modafinil publications (n = 120 patients) [17, 29, 30] The primary outcome was to expedite recovery through early rehabilitation. The 1 st case was 77-year-old male 230 with a medical history of small non-cancerous lung cells who was readmitted for respiratory distress requiring 231 intubation, then extubated and continued to require intermittent noninvasive ventilation for dyspnea and he 232 was not participating in physical therapy due to hypersomnolence. He was prescribed 200 mg modafinil every 233 morning for 13 d. At day 2, he was weaned on 3-L nasal cannula and made advances in rehabilitation. The 2 nd 234 case was a 67-year-old male with a medical history of esophageal cancer. He was admitted to ICU for 235 management of pneumonia and sepsis and received washouts for gastro-pleural fistula. After his initial surgery, 236 he was noted to be extremely fatigued and expressing wishes to withdraw care. Modafinil 200 mg every morning 237 was started and on day 2, the patient was more engaged in his care. No side effects were noted throughout the 238 8 days course. The 3 rd case was a 70-year-old male with a medical history of esophageal cancer was admitted to 239 the ICU for respiratory failure which was improved and eventually extubated. His rehabilitative status was 240 complicated by his overall lack of energy, and his waxing and waning mental status. Modafinil was started at a 241 dose of 100 -200 mg. At day 6, the patient did not need his home lorazepam 1.5 mg at night and he engaged 242 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. more in his care. The author concluded that modafinil was beneficial in the ICU owing to its effects on improving 243 sleep efficiency, adjusting circadian sleep-cycle disruption, and decreasing EDS which subsequently reduce 244 delirium, improve day-time cognition, improve wakefulness, and facilitate engagement with physical therapy 245 and rehab. Compared to those findings, our observations suggested that modafinil improves cognition and 246 increases GCS in 5 (62.5%) patients in our series, suggesting it might be reasonable for promoting wakefulness 247 in ICU patients especially in mechanically ventilated patients which have not been described in the prior case 248 series [31] . Moreover, we included more diverse cohort from transplant, surgical, and COVID-19 ICUs which had 249 not been reported in the prior literature [31, 32] . Mechanically ventilated COVID-19 patients may require higher 250 doses of opioids and sedatives to mitigate ventilator-induced lung injury, and prevent self-extubation. Deep 251 levels of sedation may also require prior to initiation of neuromuscular blocking agents (NMB) in moderate-to-252 severe acute respiratory distress syndrome (ARDS) [35] . All these factors could potentially delay the recovery of 253 neurocognitive function and increase risks of ICU acquired weakness particularly when corticosteroids are used 254 with aminosteroidal NMB [36] . However, clinicians should also be cognizant that COVID-19 patients are 255 predominately presented with hyperactive delirium, and agitation due to multiple factors including direct virus 256 invasion to CNS, prolonged mechanical ventilation, social isolation, and restricted family visitation [37] . 257 Therefore, comprehensive assessment is warranted to identify those who might benefit from modafinil as 258 wakefulness agent prior to initiation of therapy. Moreover, the most common dose of modafinil that was used 259 in our series 100 mg oral once every morning with a median duration of 4 days and was fairly tolerated. Based 260 on published data, the usual dose of modafinil is 100-400 mg (starting dose 100-200 mg oral daily with a lower 261 dose recommended for patients with cardiovascular diseases and liver cirrhosis) [31, 32] . Therefore, a less ideal 262 response in term of GCS improvement was observed in patients # 2, 7, and 8 which might be due to inadequate 263 modafinil dose. Hence, a higher dose might be reasonable to use in these situations. Regarding the safety and 264

ADRs, we used the Naranjo scale for assessment of causality and a score of 0 to -1 indicated a doubtful causality 265 of ADRs and modafinil therapy in our series [34] . The ICU complications were most likely attributed to underlying 266 comorbidities. 267 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10. 1101 /2021 Interestingly, modafinil prevented tracheostomy in one patient with COVID-19 (case 1) who was then 268 successfully extubated. A previous report showed that patients with COVID 19 who required prolonged 269 mechanical ventilation had a high mortality rate. Therefore, tracheostomy might be considered when prolonged 270 mechanical ventilation is anticipated [38] . On the other hand, studies showed that tracheostomy carries 271 significant risk of viral transmission to the healthcare workers [39] . Hence, preventing tracheostomy provided 272 advantages including shortening duration of critical care resource use (ventilators) and ICU length of stay during 273 COVID-19 outbreak, and minimizing aerosolization risks associated with this procedure for healthcare workers. 274

Furthermore, 2 patients (case # 5, and 7) has a neuroimaging that showed hemorrhagic stroke, 1 patient (case 275 #6) showed ischemic stroke with hemorrhagic transformation, a population which had not been assessed for 276 modafinil treatment in the prior literature [17, [27] [28] [29] [30] [31] [32] . Moreover, 2 (25 %) of the patients (case #4, and 5) had 277 a history of OSA. We speculated that the observed improvements in cognition and GCS of these patients 278 possibly were related to enhanced nocturnal sleep based on the drug mechanism of action; however, further 279 evaluation is still needed. The 28 d all-cause mortality rate in our series was 2 (25 %) and 90 d all-cause mortality 280 rate was 5 (62.5%) and this is possibly expected as we are a tertiary care hospital. Therefore, it is likely that our 281 patients were sicker, as the APACHEII and SOFA scores suggest that these data were derived from a cohort of 282 critically ill patients. This is comparable to the mortality rate in patients admitted to the ICU with severe sepsis 283 and shock [40] [41] [42] . 284

Our study limitations were small sample size, single institution experience, retrospective and observational in 285 nature, and lack of a control group which precludes causal interpretations. Similar to other observational 286 studies, our findings can be biased by confounding from unmeasured factors that influence cognitive function 287 and recovery such as the effect of physiotherapy and rehabilitation. It is also plausible that the increasing trend 288 in GCS over time was largely owing to the result of reduced exposure to other sedatives and analgesics and 289 spontaneous recovery. Moreover, patient-family interaction has a great impact in patient recovery as shown in 290 the recent report [43, 44] . In our series, the intensivist on service had the patient described in case 1 interact 291 with the patient's family through video calling, which likely uplifted his spirit and played a potential role in his 292 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint recovery. Additionally, the small sample size prohibited us from performing statistical analysis to assess and 293 adjust for confounders or perform analysis of what factors might be associated with response or lack thereof. 294 This may have led to an overestimation or underestimation of modafinil effect for wakefulness in the critical 295 care unit [45] . As is always the case with observation type study, association does not prove causality, but there 296 are reasonable data showing that modafinil might have potential benefits when administered to certain critically 297 ill patients especially those who appear hypoactive, lethargic, and depressed and particularly when conservative 298 treatment has failed, which provides biological plausibility [17, [27] [28] [29] [30] [31] [32] . Its daily cost is insignificant compared 299 with the high cost of an extended ICU stay although it is difficult to conclude from our experience that patients' 300 length of ICU stay was shortened. Nonetheless, we felt that it is important to report our experience to help 301 rationalize and understand the role of neurostimulants to promote arousal and wakefulness in the ICU which 302 subsequently facilitate self-expression, accelerate recovery, increase participation in physiotherapy and 303 ambulation, hastening liberation from the ventilatory support, and decrease ICU-related complications such as 304 DVT, and ICU-acquired delirium. 305

Based on our observations of these patients, the known effects of modafinil, its safety profile, and the published 306 experiences of others, we believe that modafinil might has potential benefits and that the consequences of 307 delayed patient recovery and a prolonged ICU stay may outweigh the risks of potential modafinil side effects. 308

Although we cannot state with certainty that modafinil improves cognition function and GCS in our series, it 309 seems that the timing of drug administration in concert with the putative benefits of the medication makes it a 310 plausible conclusion. 311

There are many unanswered questions that we believe would be a good starting point for a larger randomized 312 controlled trial to substantiate the ideal time of modafinil initiation, identify the population that most likely 313 benefit from therapy, define the optimal drug dose and duration, and identify the role of a combination therapy 314 and its impact on clinical outcomes. Future studies with appropriate sample size, adequate power are needed 315 to better describe its role in the ICU patients post hemorrhagic stroke. Additionally, the impact of modafinil 316 therapy on overall ICU outcomes, such as mortality, duration of mechanical ventilation, and ICU length of stay 317 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint and understand modafinil use in critically ill COVID-19 patients. However, in this pandemic setting, evidence of 319 some physiological safety and possible benefit might be considered for hypothesis generation, as shown in our 320 series. 321

Cognitive improvement after critical illness is complex. In our case series, we reviewed the literature and 323 described our center's experience for modafinil use for wakefulness in the ICU ventilated patients including 324 COVID-19 patients. Based on our observations of these patients, the known effects of modafinil, and its safety 325 profile, we believe that modafinil might has potential benefits when administered to certain critically ill patients 326 especially those who appear hypoactive, and lethargic after comprehensive assessment of potential etiologies 327 for altered mental status. Though our observations are intriguing, they result from uncontrolled, retrospective 328 chart review and confounding bias is likely which preclude definitive statements. Nevertheless, this initial 329 experience is promising and may provide preliminary evidence and hypothesis warrant to be assessed in 330 randomized controlled trials. 331 Figure  332 Table 1 : Trials on modafinil use in neuro and ICU population 333 consciousness. Time 0 the time modafinil was first administered . Improvement was noted on patient # 340 1, 3, 4, 5, 6. No improvement was noted for patient # 2, 7. Patient # 8 received modafinil twice: first trial 341 was 100 mg oral every morning for 5 days [patient 8 a] and the second trial was of 100 mg oral every 342 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint morning for 6 days [patient 8 b]. In both scenarios, the GCS slightly increased initially after modafinil 343 administration then remains unchanged after that. 344 approved the final version to be published. We confirmed that the authorship followed the uniform 364 requirements for manuscripts submitted to biomedical journals. 365 366 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint This research did not receive any specific grant from funding agencies in the public, commercial, or not-368 for-profit sectors. 369

The authors declare that they have no known competing financial interests or personal relationships that 371 could have appeared to influence the work reported in this paper. 372

The datasets used and analyzed during the current report are available from the corresponding 374 author on reasonable request. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Workup and complications Value Patient #5: Status post right frontal craniotomy for evacuation of right frontal IPH and IVH with the placement of two drains. Interval evolution of right frontal IPH and IVH and slight decrease in ventricular dilatation. Patient #6: post-surgical changes from decompressive craniectomy and evacuation of basal ganglia hematoma with large left ACA/MCA territory infarction. Interval worsening of the rightward midline shift of 1.1 cm. Interval placement of the left frontal EVD with interval improvement in the size of the right lateral ventricle. Patient #7 Day 8: Several probable embolic infarcts in the right centrum ovale and corpus callosum, mild interval improvement of the SAH, no significant interval change of the IVH and ventricular dilatation. Complication during ICU stay (n, %) Nosocomial meningitis 3 (37.5) Intra-abdominal infections 2 (25) Other infections 5 (62.5) Cardiac arrest 2 (25) Pulmonary embolism 1 (12.5) DIC 1 (12.5) HIT 1 (12.5) GIB 3 (37.5) Hemorrhagic shock 1 (12.5) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint computed tomography, DIC : disseminated intravascular coagulation, EEG: electroencephalogram, EVD: external ventricular drain, EMG and NCS: electromyogram and nerve conduction study, GIB: gastrointestinal bleeding, HIT: heparin-Induced thrombocytopenia, IPH: intraparenchymal hemorrhage, IVH: intraventricular hemorrhage, MRI: magnetic resonance imaging, MCA: middle cerebral artery, SAH: subarachnoid hemorrhage . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint 28-days all-cause mortality (n, %) 2 (25)

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.11.21250832 doi: medRxiv preprint

90-days all-cause mortality (n, %) 5 (62.5) Table Footnote Abbreviation: AC: assist-control mode, FiO2: fraction of inspired oxygen, MV: mechanical ventilation, PaO2: partial pressure of oxygen, PEEP: positive end-expiratory pressure, PCV: pressure control ventilation, PS: pressure support, PRVC: pressure-regulated volume control . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Metabolic encephalopathy: behind the name

Sleep and Intensive Care Unit-Acquired Weakness in 418

Critically Ill Older Adults. Dimens Crit Care Nurs

Clinical practice guidelines for the prevention and management 421 of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU

Multiple organ infection and the pathogenesis of SARS

The emerging spectrum of COVID-19 neurology: clinical, 426 radiological and laboratory findings

Neurologic Manifestations of Hospitalized Patients With Coronavirus 428 Disease

Neurologic features in severe SARS-CoV-2 infection

How critical illness affects the brain …and vice versa

Amantadine to improve neurorecovery in traumatic 447 brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial

The outcome of patients with severe head injuries 450 treated with amantadine sulphate

Placebo-controlled trial of amantadine for severe traumatic brain 453 injury

Amantadine and modafinil as neurostimulants during post-455 stroke care: A systematic review

Fluoxetine for motor recovery after acute ischaemic stroke 458 (FLAME): a randomised placebo-controlled trial

Effects of fluoxetine on functional outcomes after acute stroke (Focus): a 461 pragmatic, double-blind, randomised, controlled trial